NCT07466212Recruiting
QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
Impact of Concurrent Diabetes on Quality-of-life Changes During Immunotherapy - A Prospective Longitudinal Study
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is: \- How does quality of life change over six months in patients with versus without diabetes? Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 920 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 18 Mar 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Odense University Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07466212
What you commit to
- Study type: Observational
- Planned participants: 920
- From 18 Mar 2026 to the primary completion date, 1 Oct 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ICI treatment within 6 months.
- Concurrent systemic anticancer therapy other than ICI.
Other illness
- Cognitive or physical impairment preventing valid consent or completion of patient-reported outcomes.
Other
- Declines or does not provide informed consent.
Who the study is looking for
- Age ≥18 years.
- Histologically confirmed solid malignant tumor.
- Planned treatment with ICI monotherapy or dual-ICI combination therapy (metastatic, adjuvant, or neo-adjuvant settings).
- Previous systemic anticancer therapy other than ICI is allowed.
- Ability and willingness to provide written informed consent and to complete HRQoL questionnaires.
- Sufficient Danish language proficiency to read, and complete study questionnaires.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Onkologisk afdeling, Klinik Kirurgi og Kræftbehandling Coordinator of this site? Confirm its status | Aalborg | Denmark | Not yet recruiting |
| Kræftafdelingen, Aarhus Universitetshospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
| Afdeling for Kræftbehandling, Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
| Sygehus Lillebælt, Onkologisk afdeling Vejle Coordinator of this site? Confirm its status | Vejle | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.